Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMIT-2: Therapeutics for Crimean-Congo Haemorrhagic Fever
NCT06860334Phase 2Recruiting
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of favipiravir, ribavirin in Crimean–Congo hemorrhagic fever (CCHF), sponsored by Liverpool School of Tropical Medicine. Started Jun 2026; status: recruiting.
02
Drugs
favipiravirribavirin
03
Conditions
Crimean–Congo hemorrhagic fever (CCHF)
Beyond the preview
Go deeper on NCT06860334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860334.